1

Positive attribute framing increases COVID-19 booster vaccine intention for

unfamiliar vaccines.

Barnes, K. PhD[1], Colagiuri, B. PhD[1]

[1] University of Sydney, Australia

Corresponding Author:

Dr. Kirsten Barnes,

School of Psychology, A18

University of Sydney

NSW 2006

Australia

Email: kirsten.barnes@sydney.edu.au

Abstract

Positive framing has been proposed as a potential intervention to increase COVID-19 vaccination intentions. However, most available research has examined fictitious or unfamiliar treatments. This pre-registered study compared positively and negatively attribute-framed side effect information for real COVID-19 booster vaccines (AstraZeneca, Pfizer, Moderna) and measured booster intentions pre- and post-intervention in 1,222 UK-based participants. As hypothesised, vaccine familiarity significantly modulated the effect of framing. While positive framing was effective for the least familiar vaccine (i.e., Moderna), standard negative framing appeared to increase intentions for familiar vaccines (AstraZeneca/Pfizer), particularly among those with low baseline intentions. These findings provide important new evidence that positive framing could improve vaccine uptake globally when switches or new developments require individuals to receive less familiar vaccines – as is currently the case for millions of booster vaccines across the world. Positive framing of familiar vaccines, however, should be treated with caution.

Introduction

With vaccine efficacy for Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19) waning over time[1,2] and reduced for emerging variants[3,4], many countries are accelerating their COVID-19 booster programmes[5,6]. However, vaccine availability does not necessarily translate to vaccine acceptance[7], with the World Health Organization (WHO) recognising vaccine hesitancy as a global health threat[8]. Side effect apprehension is a primary factor driving hesitancy[9], with 90% of COVID-19 vaccine refusers fearing side effects more than COVID-19 itself[10]. Further, side effect severity from initial doses has been associated with booster vaccine hesitancy[11]. Reducing perceptions of side effects appears vital for increasing booster acceptance and reducing the global burden COVID-19.

The WHO[12] has suggested the framing of vaccine-relevant information[13] could provide a method of reducing negative perceptions. Positive attribute framing, where side effect information is framed in terms of the inverse incidence rate (e.g., "60% will ***not*** get a sore arm") as opposed to typical negative framing with the standard incidence rate (e.g., "40% will get a sore arm") could be particularly useful for combatting COVID-19 vaccine hesitancy. First, it is directly applicable to side effects. Second, informed consent is maintained due to statistical consistency across frames[14]. Third, there is preliminary evidence that positive attribute framing can improve vaccination attitudes in other settings. For example, one study on the influenza vaccine found positive attribute framing (hereafter positive framing) reduced the expectation and experience of side effects, increased perceived protection from influenza, and reduced distortions in the perception of side effect risk[15], with results replicated for other vaccine types[16].

The handful of studies examining framing on COVID-19 vaccine intention have

produced mixed results[17-19]. However, those studies focused on vaccine-naïve individuals, did

not employ attribute framing, and did not concern booster intentions. Further, those studies

also either used fictitious COVID-19 vaccines[17,18] or did not name specific approved COVID-

19 vaccines[19]. As such, participants either had limited knowledge of, or investment in, the

framed vaccines. As the pandemic has progressed, media discourse[20,21] combined with direct

and socially-observed experience of COVID-19 side effects[22], means it is essential to

understand whether positive framing is effective for real-world vaccines where prior

knowledge and experience exists. This is particularly important because there is reason to

believe that prior knowledge regarding a given COVID-19 vaccine may moderate the

strength of any positive framing effect.

Research has shown that greater relevance or belief in a treatment or issue decreases

the efficacy of different forms of framing[23,24], including positive framing on perceptions of

hypothetical vaccines[23,25]. The effect of positive framing on vaccine intention may therefore

be limited to less familiar vaccines. Even if so, positive framing may still hold utility. New

composition changes to COVID-19 booster vaccines have been recommended[26] and are

currently being developed[27] to protect against emerging variants. Further, many booster

programmes (e.g., in the United Kingdom) require switches from an experienced vaccine

(e.g., AstraZeneca Vaxzevria) to a less familiar one (e.g., Moderna Spikevax). Positive

framing may therefore be beneficial for increasing uptake for novel vaccines and switches to

less familiar vaccines. Yet, because research on positive framing has largely focused on

fictitious medications and patient scenarios[23,25,28-32], the extent to which familiarity moderates

the effect of positive framing is currently unclear. Therefore, to understand the extent to

which positive framing could be deployed to improve global vaccine uptake to combat

COVID-19, it is critical to test the efficacy of positive framing for genuine familiar and

unfamiliar vaccines.

In this pre-registered study (aspredicted.org/53ph4.pdf), positive attribute framing

was applied to side effects from genuine manufacturer Patient Information Leaflets (PILs) for

the AstraZeneca, Pfizer, and Moderna vaccines and compared to standard negative wording.

Participants were randomised to read positive or negatively framed PILs for the same vaccine

they had previously received (either AstraZeneca/Pfizer), a familiar vaccine in the UK

context (Pfizer/AstraZeneca), or an unfamiliar vaccine (Moderna). It was hypothesised that a)

positive framing would increase booster intention, and b) the effect of positive framing would

decrease with vaccine familiarity. Following previous research[14,28,33-35] secondary outcome

variables concerning booster side effect severity, perceived risk, and booster acceptance, as

well as prevalence judgments, were explored as potential mediators of the framing effect on

vaccine intention (see Supplementary Materials 1).

Results

Overview

Participants (*N*=1,222) were recruited from the United Kingdom via Pureprofile, an

international recruitment service, between 27th October and 8th November 2021. All were pre-

screened (see Methods) with data removed on pre-registered quality control criteria (see

Supplementary Materials 2). Only those who had received two doses of either the

AstraZeneca or Pfizer COVID-19 vaccines were eligible to participate, with participants

stratified by their previous vaccine type.

Participants from each stratum were subsequently randomised to one of six

experimental conditions (2(Framing)*3(Familiarity) factorial design; see Figure 1). Baseline

ratings were collected regarding primary and secondary outcome measures—all recorded on

a 100-point VAS. The primary outcome was the participant's intention to receive a booster

vaccine. Secondary outcomes were: 1) perceived booster side effect severity; 2) perceived

booster risk; 3) booster acceptance. Wording of items can be found in Figure 1. Familiarity

with the side effects of the AstraZeneca, Pfizer, and Moderna vaccines were additionally

assessed (100-point VAS) to determine whether side effect knowledge corresponded with the

predetermined factorial categories of vaccine Familiarity (i.e., Same > Familiar >

Unfamiliar).

Figure 1: Overview of the experimental design, including the item wording for primary and

secondary outcomes (*Nb*. analyses concerning secondary outcomes are contained in

Supplementary Materials 1).

Framed side effect information was subsequently presented dependent on condition

using genuine manufacturer PILs for the AstraZeneca, Pfizer, and Moderna vaccines, with

side effects presented in standard EU verbal prevalence categories and frequency bands.

Positive framing was applied to the frequency bands (for example see Figure 2; full wording

and PILs presented as Supplementary Materials 3-4). To manipulate familiarity, participants

were randomised to view PILs from the following conditions: 'Same' (PIL for the COVID-19

vaccine previously received: AstraZeneca-AstraZeneca|Pfizer-Pfizer); 'Familiar' (PIL for a

common vaccine not previously received: Pfizer-AstraZeneca|AstraZeneca-Pfizer);

'Unfamiliar' (PIL for a less common vaccine in the UK: AstraZeneca-Moderna|Pfizer-

Moderna). Familiarity was judged on UK data (22nd September 2021), where fewer Modena

second doses (1.2 million) had been administered relative to the Pfizer and AstraZenca

vaccine (19.4 and 24.0 million respectively)[36]. After timed PIL presentation of 2 minutes, all

participants provided post-manipulation ratings for the primary and secondary outcomes (as

above). Participants were then presented with 14 side effects from their assigned PIL and

were required to: 1) assign each to a verbal prevalence category (i.e., very common, common,

uncommon, rare, very rare); 2) estimate frequency of occurrence (number of people in

100,000 expected to experience the side effect (results in Supplementary Materials 1.4.1).

Negative Attribute Frame (Standard EU Wording)	Positive Attribute Frame	Positive Attribute Frame (Accompanying Infographic)	
Common (may affect up to 1 in 10 people)	**Common** (90 in 100 or more people may **_not be affected_**)		**Common:** 90 in 100 (blue circles) or more **not** affected
Uncommon (may affect up to 1 in 100 people)	**Uncommon** (990 in 1,000 or more people may **_not be affected_**)		**Uncommon:** 990 in 1,000 (blue circles) or more **not** affected

Figure 2: Positive and negative wording used to frame common and uncommon side effects

(wording for all prevalence categories can be found in Supplementary Materials 3)

Descriptive Statistics

Sample demographics

Information regarding participant location, age, education, and employment can be found

in Figure 2a-b. Participants were 52.5 years of age on average (range=18-95). They resided

across most postal areas in the UK, with the largest proportion from London district (*N*= 53),

Birmingham (*N*=35), and Belfast (*N*=34). Only Harrogate, and the Orkney and Shetland Islands

were not represented. The largest proportion of respondents identified as British (*N*=1,064;

87%), female (*N*=706; 58%), had completed undergraduate-level education (*N*=413; 34%), and

were in full-time employment (*N*=407; 33%). Descriptive statistics for the full sample, and by

condition, are presented as Supplementary Materials 5-6.

COVID-19 exposure and vaccine history

Most participants (N=1,074; 88%) had not personally been infected with COVID-19,

while 565 (46%) reported infections among family and close friends. On average, participants

had their last COVID-19 vaccine 4.8 months ago. The largest proportion reported not

experiencing side effects to either dose (N=579; 47%). Of those who did, the first dose was most

associated with severe side effects (N=372; 30%).

Figure 3: Demographic Information, where 3a plots the frequency of participants from each postal area of the UK against the

vaccination rates reported by the UK government on the 3rd November (the final week of data collection) and 3b depicts education and

employment categories, and age range, across experimental conditions. *Nb*. 6 participants, 0.5% of the sample, are not represented in

3a due to not providing a valid postal code.

Primary Analysis

>>> ***Knowledge of vaccine side effects mirrors categorical levels of the Familiarity factor***

To determine whether side effect familiarity corresponded with the predetermined factorial categories of Familiarity (i.e., Unfamiliar, Familiar, Same), a within-subjects one-way ANOVA (with Greenhouse–Geisser correction) was run on side effect familiarity ratings collected for the three vaccine types prior to the experimental manipulation. A robust main effect of Familiarity was observed ($F(1.86, 2272.18)=659.17$, $p<.001$, $\eta_p^2=.35$). Awareness of side effects increased with Familiarity; being higher for the Same vs. Familiar vaccine ($t(1221)=14.11$, $p<.001$, Cohen's $d_z=.40$), and for the Familiar vs. Unfamiliar vaccine ($t(1221)=23.97$, $p<.001$, Cohen's $d_z=.69$). Mean differences are presented in Figure 4e.

>>> ***Baseline vaccine intention***

A 2(Framing)*3(Familiarity) ANOVA was conducted on Baseline Booster Intention scores to assess the presence of between-group differences. Baseline Booster Intention was anticipated to be high across conditions (see pre-registration), which was confirmed in the present sample ($M=78.36$ (/100-point VAS), $SD=31.65$; range:0-100). However, an unanticipated significant effect of Familiarity was observed($F(2, 1216)=49.51$, $p<.0001$, $\eta_p^2=.075$). This effect reached significance for the orthogonal contrast comparing the Same vs. Other (i.e., combined Familiar and Unfamiliar) vaccine types ($F(1, 1216)=96.51$, $p<.0001$, $\eta_p^2=.074$), but not for the Familiar vs. Unfamiliar comparison ($F(1, 1216)=2.42$, $p=.120$, $\eta_p^2=.002$), indicating higher intentions for previously experienced vaccines.

>>> ***Effect of Framing and Familiarity on the intention to be vaccinated***

The pre-registered primary analysis plan was a 2(Framing: Positive vs. Negative)*3

(Familiarity: Same, Familiar, Unfamiliar) factorial ANCOVA, with Baseline Booster Intention

for the vaccine presented in the participant's assigned PIL as the covariate, and Post-

Manipulation Booster Intention the outcome. However, the fact that Baseline Intention

unexpectedly differed systematically with Familiarity meant that including it as a covariate

without including its interactions with the manipulated variables (Framing and Familiarity)

would violate the assumptions of ANCOVA[37]. To address this, we extended the model to include

the interactions between Baseline Booster Intention and Framing and Familiarity in all analyses,

as recommended elsewhere[38]. Pre-specified orthogonal contrasts for Familiarity were: Contrast1

(Same vs. Other [Familiar and Unfamiliar combined]); Contrast2 (Familiar vs. Unfamiliar). A

Framing*Familiarity interaction was hypothesised, with the effect of Framing (increased Booster

Intention following Positive vs. Negative framing) reducing with increased Familiarity.

Main effects analysis revealed the anticipated Framing*Familiarity interaction ($F(2,$

$1210)=10.75$, $p<.0001$, $\eta_p^2=.018$). Specifically, Framing interacted with Contrast1 (Same vs.

Other: $F(1, 1210)=5.07$, $p=.025$, $\eta_p^2=.004$) and Contrast2 (Familiar vs. Unfamiliar: $F(1,$

$1210)=16.46$, $p=.0001$, $\eta_p^2=.013$). As demonstrated in Figure 4a, this pattern of results was

driven by Positive Framing increasing Booster Intention for the Unfamiliar vaccine. However,

this was superseded by a three-way interaction with Baseline Booster Intention ($F(2,$

$1210)=7.65$, $p=.0005$, $\eta_p^2=.013$), represented at both Contrasts (Baseline*Framing*Contrast1:

$F(1, 1210)=4.39$, $p=.036$, $\eta_p^2=.004$ | Baseline*Framing*Contrast2: $F(1, 1210)=11.19$, $p=.0008$,

$\eta_p^2=.009$). Figure 4b depicts this interaction. Positive Framing had limited efficacy at high levels

of Baseline Intention across Conditions but took effect for the Unfamiliar Vaccine when model

estimated Baseline Intention scores were lower than ~80/100. At very low levels of Baseline

Intention (i.e., VAS=0), model predicted Booster Intention Post-Manipulation increased from

M=19.09 (SEM=2.76, 95% CIs[13.68, 24.50]) for the Negative Frame, to M=35.11 (SEM=2.77,

95% CIs[29.68, 40.50]) for the Positive Frame. Full model output is included as Supplementary

Materials 7. We note that the same interaction between Framing and Familiarity was observed in

the planned but invalid model excluding the interaction between these factors and Baseline

Booster Intention (see Supplementary Materials 8).

The effect of Framing on vaccine switches

Analyses were performed to investigate the effect of framing on pre-registered and

realistic vaccine switches occurring as part of the UK's booster programme. Specifically, those

without medical exemption, who previously received the AstraZeneca vaccine will be required to

switch to Pfizer or Moderna, while those who received Pfizer may be required to switch to

Moderna.

First, previous vaccine type (AstraZeneca/Pfizer) was entered as a factor in the

ANCOVA model above to check for interactions with Framing, Familiarity, and Baseline

Booster Intention. While there was a main effect of previous vaccine type (F(1, 1198)=6.36,

p=.012, η_p^2=.005), with those receiving AstraZeneca reporting increased Booster Intention

(M=80.83, SEM= 0.74, 95% CIs [79.37, 82.29]) compared to Pfizer (M=78.01, SEM= 0.74, 95%

CIs [76.57, 79.46]), there were no two- or three-way interactions with Framing or Familiarity (all

ps>.05; see Supplementary Materials 9).

Previous vaccine: AstraZeneca

Representative of a switch from AstraZeneca to Pfizer or Moderna, a

2(Framing)*2(Familiarity: Familiar (Pfizer), Unfamiliar (Moderna)) ANCOVA (modelling

interactions between covariate and factors), was conducted among those who had previously

received the AstraZeneca vaccine (N=410). A three-way Framing*Familiarity*Baseline Intention

interaction was observed (F(1, 402)=11.38, p=.0008, η_p^2=.028). As demonstrated in Figure 4c, in

the case of the Unfamiliar vaccine (Moderna) Booster Intention was increased in the Positive

Frame at low levels of Baseline Booster Intention. However, the inverse of this pattern was

observed for the Familiar vaccine (Pfizer), where Positive Framing decreased Booster Intention

at low levels of Baseline Intention.

Previous vaccine: Pfizer

Representative of a switch from Pfizer to Moderna, a one-way ANCOVA investigating

the effect of framing on the perception of the Unfamiliar (i.e., Moderna) PIL was performed on

the data of those who had previously received the Pfizer vaccine (N=202). There was a main

effect of Framing (F(1, 198)=3.98, p=.048, η_p^2=.020), but no statistically significant Baseline

Booster Intention*Framing interaction (F(1, 198)=1.80, p=.181, η_p^2=.009). However, as

demonstrated in Figure 4d, slopes for the Positive and Negative Frame converged at high levels

of Baseline Booster Intention.

Figure 4: Model estimated mean differences in the primary outcome (Booster Intention),

depicted for the whole sample (4a and 4b), and for realistic switches occurring as part of the UK

booster programme (4c and 4d). 4e presents data demonstrating that side effect familiarity

ratings scaled with the factorial levels of Vaccine Familiarity. All error bars represent ± 1SEM.

Discussion

Message framing has been suggested as a potential intervention to increase COVID-19

vaccine uptake[12]. We examined the effect of positive and negative attribute framing of side effect

information on booster intentions for three genuine COVID-19 vaccines varying in familiarity.

Positive framing successfully increased booster intention for the unfamiliar vaccine (i.e.,

Moderna), but reduced intention for the vaccine previously received, as well as for a switch to

Pfizer among those previously receiving AstraZeneca. In all cases, effects were strongest at low

baseline booster intentions. Increasing booster acceptance among those with low intentions is of

substantial importance in protecting against infection from, and transmission of, COVID-19

viruses. Critically, our data suggest that any intervention intending to employ attribute framing

should be carefully tailored to match the framed information (positive vs. negative wording) with

vaccine familiarity. Specifically, positive framing appears to have significant potential in

situations where a novel vaccine or composition changes are being introduced[26,27]. By contrast,

positive framing may actually be harmful when the vaccine is familiar.

The effect of positive attribute framing on booster intentions for the Unfamiliar vaccine is

consistent with medical decision-making research. In these studies, framed information has

typically been presented regarding fictitious medications and patient scenarios[23,25,28-32]. When

employing real treatments, data has been collected from samples where participants were

completely[15,39] or largely[40] naïve to the framed treatment, or where prior treatment experience

was not assessed[16,41]. The current data thereby provide new insights into the effect of framing.

Under conditions directly relevant to the COVID-19 pandemic (i.e., for real vaccines, at high

levels of public involvement), the benefit of positive attribute framing was found to wane, or be

reversed, as familiarity and prior experience with the framed vaccine increased. As such, calls

for all PILs to employ positive framing as standard (e.g.,[28,42]) appear premature. Instead, negative

framing, the standard form for communicating side effect information within the European

Union, appears beneficial when treatments are well known.

The reduced efficacy of positive framing with increased vaccine familiarity could be

explained by a current theory of attribute framing that posits an interaction between familiarity (a

manifestation of psychological distance) and the valence of the message surrounding a given

attribute or event (e.g., the experience of vaccine side effects). At closer psychological distances

(e.g., for vaccines that are more familiar and more likely to be received), negatively framed

information has been shown to be more persuasive[43]. Further experimental research is needed to

test this theory, while considering alternative explanations, such as the role of potential backfire

effects in persuasive or corrective messaging. Such effects are known to impact attitudes

surrounding the COVID-19 pandemic[44] and have been demonstrated to lower intentions for other

vaccine types at high levels of concern[45]. However, when assessed in conjunction, current results

highlight the fact that any intervention that strives to apply positive framing across all vaccine

types, irrespective of familiarity, should be treated with caution.

The psychological mechanisms underlying the effect of positive framing on booster

intentions remain unclear. We measured secondary variables as potential mediators. However,

results did not mirror those obtained for the primary outcome – booster intention (see

Supplementary Materials 1). While changes in secondary variables (side effect severity and

booster acceptance) were observed with framing, post-hoc analysis (see Supplementary

Materials 10) plotting the Familiarity*Framing*Baseline interaction for those who had high vs.

low baseline booster intent, suggested that these framing-induced changes largely occurred

among those with high vaccine intention at baseline. As these participants also showed limited

effect of framing on their behavioural intention to be vaccinated, the relationship between

booster intention and our secondary predictors appears orthogonal. Investigation of other factors

combined with qualitative research may be better positioned to identify the driving factors

behind the effect of framing on COVID-19 booster intentions. Further, we note that, consistent

with previous reports[35,46-49], prevalence judgements were poor (<~35% accuracy; Supplementary

Materials 1.4). This appeared exacerbated among those receiving positive framing, but again did

not differ by familiarity. As side effects differed by PIL, the current study was designed only to

test for general inaccuracies in side effect representation and not systematic over- or under-

estimation. Experimental studies are therefore needed to assess precisely how any inaccuracies

associated with positively framed COVID-19 vaccine information manifest.

The primary strength of the present study is the application of attribute framing to real

COVID-19 vaccine information. The PILs employed here are displayed on government and NHS

websites in the UK, forming a primary official source of information regarding COVID-19

vaccination. Our findings therefore have real-world implications, demonstrating that the wording

of PILs can directly impact the intention to receive a booster vaccine among individuals for

whom this decision is both directly relevant and imminent. There are of course some limitations

worth noting including the collection of cross-sectional data that limits an assessment of the

durability of the framing effect, as well as a sample located within a single country. Given global

differences in booster policy, cross-cultural replication of results is required to ensure results are

not contextually limited to the UK. While vaccine intention has been demonstrated to be a strong

predictor of vaccine uptake (e.g.,[50-52]), including for COVID-19 vaccination[53], we do not assume

that the two are synonymous[54]. While beyond the scope of the present study, we recommend that

future research incorporate longitudinal designs where the rate of conversion from intention to

vaccine uptake can be tracked. Further, present results are specific to booster intentions among

those already vaccinated. While side effect apprehension has been associated with hesitancy

regarding COVID-19 vaccination[9] and booster vaccination[11], whether a similar pattern of results

would hold among those who have never been vaccinated is unknown.

In summary, the present study demonstrates that the ability of positive framing to

successfully increase booster intention for genuine COVID-19 vaccines is critically moderated

by the familiarity of that vaccine. Positive framing can improve vaccine intention for unfamiliar

vaccines, but may actually decrease intentions for familiar vaccines. The data therefore provide

novel insights into the benefits of positive framing for COVID-19 vaccines and beyond. As such,

we recommend that if positive attribute framing is to be employed, close attention must be paid

to the type of treatment being framed as well as the likely recipients of the framed information.

Importantly, in the context of the current COVID-19 pandemic, positive framing appears capable

of improving uptake of COVID-19 vaccines when switches or new developments require

individuals to receive unfamiliar vaccines, as is the case for many booster vaccine programmes

globally.

351　　　　　　　　　　　　　　　　　　　**Methods**

Recruitment and Sample

Recruitment took place in the initial weeks of the UK booster programme (27th October -

8th November 2021). Figure 3a provides a summary of the number of boosters administered in

the UK at the time of data collection. The sample was obtained from Pureprofile, an ISO-

certified panel provider for online research, and balanced on national quotas for age, gender, and

region. All potential participants were screened using the following inclusion criteria: 18 years of

age or older, currently residing in the UK, self-reported English fluency, previously received two

doses of either the Pfizer or the AstraZeneca COVID-19 vaccines (no other combination), not

having received a third COVID-19 booster vaccine, and no known medical reason (e.g., allergy)

prohibiting potential administration of the Pfizer, AstraZeneca, or Moderna COVID-19 vaccines.

After screening, 1896 participants provided electronic consent and 1459 completed the

experiment. To reduce statistical noise due to random and inconsistent responding, 237

completing participants were removed based on pre-registered quality control criteria (see

Supplementary Materials 2). The experiment was approved by the University of Sydney Human

Research Ethics Committee. All completing participants were provided with an electronic

debrief at the end of the survey and were paid £3.50 for a ~15-minute survey.

Data Collection and Procedure

Cross-sectional data were collected online via Qualtrics, with the survey accessible to

personal computer, tablet, and smartphone. The 'force response' option was used to ensure

complete cases for all outcome variables. Participants completed the survey in one sitting and

were not able to return to the study URL. After pre-screening, those meeting the inclusion

criteria were provided with a participant information statement detailing the aims of the study

and gave their digital informed consent. Those not meeting these criteria were directed away

from the survey.

Participants completed demographic items and identified which COVID-19 vaccine they

had previously received (AstraZeneca or Pfizer). Stratified randomisation to the six experimental

groups occurred at this point using the inbuilt Qualtrics randomisation function. Quotas were set

to limit data collection to 600 participants from each vaccine type (AstraZeneca/Pfizer), with 100

from each group randomised to the six experimental conditions. Because Qualtrics tallies quotas

on survey completion but does not account for participants currently in the experimental

pipeline, the final sample contained 22 more participants than projected. Statistical analysis did

not take place until after exclusions had been made and all quotas were closed.

After randomisation, participants responded to items concerning the number of months

since their last COVID-19 vaccine and familiarity with side effects of the three framed vaccines.

For each vaccine type, participants then rated their booster intention, perceived booster side

effect severity, perceived booster risk, and booster acceptance (satisfaction, happiness, and

anxiety). Responses made to the vaccine type that matched with the experimental condition to

which the participant had been assigned were employed as baseline measures. Responses to all

other vaccine types were recorded for use in a concurrent, but separate, pre-registered study

(#78370; aspredicted.org/8e6af.pdf). PILs containing the positively or negatively framed side

effect information were then displayed for two minutes, using a timer embedded in the survey.

Participants could not proceed until this time had elapsed. Post-manipulation booster intention,

perceived booster side effect severity, perceived booster risk, and booster acceptance were then

recorded. Finally, fourteen side effects described in the PILs were presented, with participants

required to assign each to a verbal prevalence descriptor (very common, common, uncommon,

rare, very rare) and estimate how many people (out of 100,000) taking the vaccine would

experience the side effect. On completing the survey, all participants were provided with an

electronic debrief for download and URLs to the UK government landing page where the

original PILs for the vaccines used in the study could be found.

Several additional items concerning general COVID-19 booster intentions, perceived risk

of previous COVID-19 vaccines, specific COVD-19 vaccination side effects, general perceptions

of COVID-19 and COVID-19 vaccinations, and severity of previous COVID-19 infection, were

included in the survey for use in a separate pre-registered study (for information see: #78370;

aspredicted.org/8e6af.pdf).

Survey Materials

Demographic information

Participants responded to items concerning their age, gender, ethnicity, highest level of

education and employment status, and geographic region (postal area code). Exact wording can

be found in the Demographic Information section, Supplementary Materials 5.

Previous exposure to COVID-19

Items were employed to capture personal exposure to COVID-19, as well as exposure

through close friends and family. Item wording (*To your knowledge, are you, or have you been,*

infected with COVID-19? / To your knowledge, have any of your close family members or friends

been infected with COVID-19?) was taken from the WHO BeSD documentation[12].

Previous COVID-19 vaccination history

Previous COVID-19 vaccine (Pfizer/AstraZeneca) was recorded as a forced-choice

option. Participants indicated the number of months since their last COVID-19 vaccine, and

whether their most severe side effects occurred to their first dose, second dose, whether they

were equal across doses, or not experienced at all.

Familiarity with COVID-19 vaccine side effects

For the three framed vaccines, participants were asked to rate their "*familiarity with the*

potential side effects" on a 100-point VAS, with anchor labels (*'not at all familiar'* / *'extremely*

familiar') positioned to the left and right of the scale. Those who had not heard of the vaccine

were asked to check a separate '*not heard of vaccine'* box but received a score of zero (*not at all*

familiar). This response-type was used to exclude inconsistent responders (see Supplementary

Materials 2).

Baseline measures: COVID-19 vaccine perceptions

Four items were used as baseline measures. All were rated on a 100-point VAS. For each

of the three vaccines, participants responded to questions concerning: 1) booster intention *'If you*

were offered [vaccine type] *as a booster vaccine to maintain protection against COVID-19*

viruses, how likely would you be to accept?' (labels: *'definitely would not accept vaccine'* vs.

'definitely would accept vaccine'); 2) perceived booster side effect severity *'Overall, how severe*

do you think the [vaccine type] *side effects are?'* (labels: *'not at all severe'* vs. *'extremely*

severe'); 3) perceived booster risk *'What do you think the risk to your health would be if you*

received [vaccine type] *as a booster vaccine, bearing in mind its side effects?'* (labels:

'extremely low risk' vs. *'extremely high risk'*); 4) booster switch perceptions *'Imagine that*

switching to the [vaccine type] *vaccine was your only option for a booster. Please rate how*

satisfied, happy, and anxious, you would be with this outcome' (labels: *'not at all'* vs.

'extremely'). Satisfaction, happiness, and anxiety were rated as sub-items, each yielding a score

of 0 – 100. Where the vaccine type was the same as that previously received by the participant,

wording was changed from 'switching to' to 'continuing with'. Wording of 1 – 3 was adapted

from previous research[35].

Patient Information Leaflets (PILs): Experimental manipulation

Genuine PILs for the AstraZeneca, Pfizer, and Moderna vaccine were abridged to include

the manufacturer's description of each vaccine, what it is used for, and critically, the possible

side effects resulting from administration. Side effects were retained in their original form and

order. For both the negatively and positively framed PILs, verbal descriptors were in keeping

with those published by the manufacturer (i.e., very common, common, uncommon, rare, very

rare, not known). Wording of assigned frequency bands employed in the negatively framed PILs

was also identical to that of the manufacturer. However, this was inverted in the positively

framed PILs to stress the number of individuals *not* affected (e.g., "Common (90 in 100 or more

people may *not be affected*)"). As multi-modal forms of side effect presentation (e.g., written,

pictorial, verbal) may elicit larger framing effects[14], and numeracy is less likely to moderate the

effect of attribute framing for graphical presentations[55], positive PILs additionally included a

graphical representation of side effect risk to enhance the manipulation. For an example of the

wording used to frame side effects see Figure 2.

Post-manipulation measures: COVID-19 vaccine perceptions

Participants responded to the four vaccine perception items listed above under Baseline

Measures (booster intention, booster side effect severity, booster risk, booster acceptance), but

only in relation to the vaccine type outlined in the PIL to which they were assigned.

Post-manipulation side effect perceptions

To determine whether positive framing augments the perception of side effect occurrence

relative to true prevalence rates, fourteen side effects were presented from each PIL. Eleven of

these were associated with concrete prevalence brackets in the original PILs, while the remaining

three were assigned to the 'unknown' category (i.e., could not be estimated at the time of PIL

publication). For each side effect, participants were required to identify the correct verbal

descriptor (very common, common, uncommon, rare, very rare): "*based on the information that*

you read, how common do you think [side effect] *is?"* (forced-choice answer). They were then

asked, "*In 100,000 people, how many do you think would experience* [side effect] *if they received*

a [framed vaccine name] *booster vaccine?"* (free-response, limited to numbers at up to 10

decimal places). The three 'unknown' side effects were analysed separately to determine the

effect of framing when prevalence rates are not provided.

Statistical Analysis

Statistical analysis was performed using R (version 4.1.1). Statistical analyses were a

combination of ANCOVAs (where baseline measures were available) or ANOVAs, reported

with Type III Sum of Squares. An alpha of .05 was accepted as the threshold for statistical

significance. Sample size (estimated N=1200) was calculated based on an *a priori* power analysis

(95% power, alpha=.05, effect size f^2=0.02) for a separate study run concurrently that contained

more predictor variables (N=9), and therefore required more power, than the study presented

here (further details contained in the study pre-registration form). An effect size for attribute

framing was additionally derived from previous research (average effect size r= 0.175)[14]. An *a*

priori power analysis based on this effect size required a total of 491 participants, providing

reassurance that the projected sample size for the study above provided ample power to detect an

effect of framing in the present study.

Acknowledgements

Sources of Funding: This research was supported by Australian Research Council grants

DP180102061 and DP200101748. The funding body had no involvement in study design,

analysis, interpretation, writing, or the decision to submit the present article for publication.

Data Availability: The code and raw data necessary to replicate the reported analysis is

available through the Open Science Framework repository (means/SEMs needed to reproduce

the analysis figures are included with the raw data):

https://osf.io/d5cvn/?view_only=500c83d90bb9416796e464108ad2fc41

Author contributions: KB and BC conceived the experimental design. KB was responsible for

collecting and analysing the data. KB wrote the first draft of the article. BC edited and

contributed to the final version.

References
515

1   Andrews, N. *et al.* Vaccine effectiveness and duration of protection of Comirnaty,

Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. Preprint at:

https://www.medrxiv.org/content/10.1101/2021.09.15.21263583v2 (2021).

2   Goldberg, Y. *et al.* Waning immunity of the BNT162b2 vaccine: A nationwide study

from Israel. Preprint at:

https://www.medrxiv.org/content/10.1101/2021.08.24.21262423v1(2021).

3   Cele, S. *et al.* SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer

BNT162b2 elicited neutralization and requires ACE2 for infection. Preprint at:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669855.2/ (2021).

4   Basile, K. *et al.* Improved neutralization of the SARS-CoV-2 Omicron variant after

Pfizer-BioNTech BNT162b2 COVID-19 vaccine boosting. Preprint at:

https://www.biorxiv.org/content/10.1101/2021.12.12.472252v1.abstract (2021).

5   Mahase, E. Covid-19 booster vaccines: What we know and who's doing what. *BMJ* **374**,

n2082 (2021).

6   *All adults to be offered COVID-19 boosters by end of January* (gov.uk, 2021);

https://www.gov.uk/government/news/all-adults-to-be-offered-covid-19-boosters-by-end-

of-january

7   MacDonald, N. E. Vaccine hesitancy: Definition, scope and determinants. *Vaccine* **33**,

4161-4164 (2015).

8   *Ten threats to global health in 2019* (World Health Organisation, 2019);

https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019

9   Solís Arce, J. S. *et al.* COVID-19 vaccine acceptance and hesitancy in low- and middle-

income countries. *Nature Medicine* **27**, 1385-1394 (2021).

10 *Why won't Americans get vaccinated?* (Economist/YouGov poll, 2021);

https://today.yougov.com/topics/politics/articles-reports/2021/07/15/why-wont-

americans-get-vaccinated-poll-data

11 Rzymski, P., Poniedziałek, B. & Fal, A. Willingness to Receive the Booster COVID-19

Vaccine Dose in Poland. *Vaccines* **9**, 1286 (2021).

12 *World Health Organization. Data for action: achieving high uptake of COVID-19*

vaccines: gathering and using data on the behavioural and social drivers of vaccination:

a guidebook for immunization programmes and implementing partners: interim

guidance, 1 April 2021. (World Health Organization, 2021);

https://apps.who.int/iris/handle/10665/340645

13 Levin, I. P., Schneider, S. L. & Gaeth, G. J. All Frames Are Not Created Equal: A

Typology and Critical Analysis of Framing Effects. *Organizational Behavior and Human*

Decision Processes **76**, 149-188 (1998).

14 Barnes, K. *et al.* Can Positive Framing Reduce Nocebo Side Effects? Current Evidence

and Recommendation for Future Research. *Frontiers in Pharmacology* **10**, 167 (2019).

15 O'Connor, A. M., Pennie, R. A. & Dales, R. E. Framing effects on expectations,

decisions, and side effects experienced: The case of influenza immunization. *Journal of*

Clinical Epidemiology **49**, 1271-1276 (1996).

16 Bigman, C. A., Cappella, J. N. & Hornik, R. C. Effective or ineffective: Attribute framing

and the human papillomavirus (HPV) vaccine. *Patient Education and Counseling* **81**,

S70-S76 (2010).

17 Sudharsanan, N., Favaretti, C., Hachaturyan, V., Bärnighausen, T. & Vandormael, A.

Effects of Side-Effect Risk Framing Strategies on COVID-19 Vaccine Intentions in the

United States and the United Kingdom: A Randomized Controlled Trial. Preprint at:

https://www.medrxiv.org/content/10.1101/2021.10.12.21264877v2 (2021).

18 Chen, T., Dai, M., Xia, S. & Zhou, Y. Do Messages Matter? Investigating the Combined

Effects of Framing, Outcome Uncertainty, and Number Format on COVID-19

Vaccination Attitudes and Intention. *Health Communication*, 1-8 (2021).

19 Huang, Y. & Liu, W. Promoting COVID-19 Vaccination: The Interplay of Message

Framing, Psychological Uncertainty, and Public Agency as a Message Source. *Science*

Communication **44**, 3-29 (2021).

20 Lentzen, M.-P. *et al.* A retrospective analysis of social media posts pertaining to COVID-

19 vaccination side effects. *Vaccine* **40**, 43-51 (2022).

21 Jamison, A. M. *et al.* Vaccine-related advertising in the Facebook Ad Archive. *Vaccine*

38, 512-520 (2020).

22 Ndwandwe, D. & Wiysonge, C. S. COVID-19 vaccines. *Current Opinion in Immunology*

71, 111-116 (2021).

23   Donovan, R. J. & Jalleh, G. Positive versus Negative Framing of a Hypothetical Infant
Immunization: The Influence of Involvement. *Health Education & Behavior* **27**, 82-95
(2000).

24   Benjamin, D., Por, H.-H. & Budescu, D. Climate Change Versus Global Warming: Who
Is Susceptible to the Framing of Climate Change? *Environment and Behavior* **49**, 745-
770 (2016).

25   Haydarov, R. & Gordon, J. C. Effect of combining attribute and goal framing within
messages to change vaccination behavior. *Journal of Communication in Healthcare* **8**,
45-54 (2015).

26   *Interim Statement on COVID-19 vaccines in the context of the circulation of the Omicron*
SARS-CoV-2 Variant from the WHO Technical Advisory Group on COVID-19 Vaccine
Composition (TAG-CO-VAC) (World Health Organization, 2022);
https://www.who.int/news/item/11-01-2022-interim-statement-on-covid-19-vaccines-in-
the-context-of-the-circulation-of-the-omicron-sars-cov-2-variant-from-the-who-technical-
advisory-group-on-covid-19-vaccine-composition

27   Pfizer plans to manufacture up to 100 million doses of omicron-specific vaccine by
spring (*The Washington Post,* 2022);
https://www.washingtonpost.com/business/2022/01/11/pfizer-omicron-specific-vaccine/

28   Webster, R. K. & Rubin, G. J. The Effect of Positively Framing Side-Effect Risk in Two
Different Formats on Side-Effect Expectations, Informed Consent and Credibility: A
Randomised Trial of 16- to 75-Year-Olds in England. *Drug Safety* **43**, 1011-1022 (2020).

29   Krishnamurthy, P., Carter, P. & Blair, E. Attribute Framing and Goal Framing Effects in
Health Decisions. *Organizational Behavior and Human Decision Processes* **85**, 382-399
(2001).

30   Levin, I. P., Schnittjer, S. K. & Thee, S. L. Information framing effects in social and
personal decisions. *Journal of Experimental Social Psychology* **24**, 520-529 (1988).

31   Zimmermann, C., Baldo, C. & Molino, A. Framing of outcome and probability of
recurrence: Breast cancer patients' choice of adjuvant chemotherapy (ACT) in
hypothetical patient scenarios. *Breast Cancer Research and Treatment* **60**, 9-14 (2000).

32   Marteau, T. M. Framing of information: Its influence upon decisions of doctors and
patients. *British Journal of Social Psychology* **28**, 89-94 (1989).

33   Webster, R. K. & Rubin, G. J. Predicting Expectations of Side-Effects for Those Which
Are Warned Versus Not Warned About in Patient Information Leaflets. *Ann Behav Med*
12, 1253–1261 (2021).

34   Herber, O. R., Gies, V., Schwappach, D., Thürmann, P. & Wilm, S. Patient information
leaflets: informing or frightening? A focus group study exploring patients' emotional
reactions and subsequent behavior towards package leaflets of commonly prescribed
medications in family practices. *BMC Family Practice* **15**, 163 (2014).

35   Berry, D. C., Raynor, D. K. & Knapp, P. Communicating risk of medication side effects:
An empirical evaluation of EU recommended terminology. *Psychology, Health &*
Medicine **8**, 251-263 (2003).

36   *Research and analysis: Coronavirus vaccine - weekly summary of Yellow Card reporting*
(gov.uk, 2021); https://www.gov.uk/government/publications/coronavirus-covid-19-
vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting

37   Myers, J. L. & Well, A. D. *Research design and statistical analysis, 2nd ed*. (Lawrence
Erlbaum Associates Publishers, 2003).

38   Cardinal, R. N. & Aitken, M. R. F. *ANOVA for the behavioural sciences researcher*.
(Lawrence Erlbaum Associates Publishers, 2006).

39   Llewellyn-Thomas, H. A., McGreal, M. J. & Thiel, E. C. Cancer Patients' Decision
Making and Trial-entry Preferences: The Effects of "Framing" Information about Short-
term Toxicity and Long-term Survival. *Medical Decision Making* **15**, 4-12 (1995).

40   Ferguson, E. & Gallagher, L. Message framing with respect to decisions about
vaccination: The roles of frame valence, frame method and perceived risk. *British*
Journal of Psychology **98**, 667-680 (2007).

41   Jasper, J. D., Goel, R., Einarson, A., Gallo, M. & Koren, G. Effects of framing on
teratogenic risk perception in pregnant women. *The Lancet* **358**, 1237-1238 (2001).

42   Webster, R. K., Weinman, J. & Rubin, G. J. Explaining all without causing unnecessary
harm: Is there scope for positively framing medical risk information? *Patient Education*
and Counseling **102**, 602-603 (2019).

43   Freling, T. H., Vincent, L. H. & Henard, D. H. When not to accentuate the positive: Re-
examining valence effects in attribute framing. *Organizational Behavior and Human*
Decision Processes **124**, 95-109 (2014).

44   Dan, V. & Dixon, G. N. Fighting the Infodemic on Two Fronts: Reducing False Beliefs
639   Without Increasing Polarization. *Science Communication* **43**, 674-682 (2021).

640   45   Nyhan, B. & Reifler, J. Does correcting myths about the flu vaccine work? An
641   experimental evaluation of the effects of corrective information. *Vaccine* **33**, 459-464
642   (2015).

643   46   Webster, R. K., Weinman, J. & Rubin, G. J. People's Understanding of Verbal Risk
644   Descriptors in Patient Information Leaflets: A Cross-Sectional National Survey of 18- to
645   65-Year-Olds in England. *Drug Safety* **40**, 743-754 (2017).

646   47   Berry, D. C., Knapp, P. R. & Raynor, T. Is 15 per cent very common? Informing people
647   about the risks of medication side effects. *International Journal of Pharmacy Practice*
648   **10**, 145-151 (2002).

649   48   Berry, D. C., Raynor, D. K., Knapp, P. & Bersellini, E. Patients' Understanding of Risk
650   Associated with Medication Use. *Drug Safety* **26**, 1-11 (2003).

651   49   Knapp, P. *et al.* Communicating the Risk of Side Effects to Patients. *Drug Safety* **32**, 837-
652   849 (2009).

653   50   Gerend, M. A. & Shepherd, J. E. Predicting Human Papillomavirus Vaccine Uptake in
654   Young Adult Women: Comparing the Health Belief Model and Theory of Planned
655   Behavior. *Annals of Behavioral Medicine* **44**, 171-180 (2012).

656   51   Lehmann, B. A., Ruiter, R. A. C., Chapman, G. & Kok, G. The intention to get
657   vaccinated against influenza and actual vaccination uptake of Dutch healthcare personnel.
658   *Vaccine* **32**, 6986-6991 (2014).

659   52   Juraskova, I., Bari, R. A., O'Brien, M. T. & McCaffery, K. J. HPV Vaccine Promotion:
660   Does Referring to Both Cervical Cancer and Genital Warts Affect Intended and Actual
661   Vaccination Behavior? *Women's Health Issues* **21**, 71-79 (2011).

662   53   Jensen, U., Ayers, S. & Koskan, A. *Video-based messages to reduce COVID-19 vaccine*
663   *hesitancy and nudge uptake*. Preprint at: https://psyarxiv.com/df9qw/ (2021).

664   54   Sheeran, P. Intention—Behavior Relations: A Conceptual and Empirical Review.
665   *European Review of Social Psychology* **12**, 1-36 (2002).

666   55   Kreiner, H. & Gamliel, E. Are highly numerate individuals invulnerable to attribute
667   framing bias? Comparing numerically and graphically represented attribute framing.
668   *European Journal of Social Psychology* **47**, 775-782 (2017).

Pre-Screened Participants
(Total N = 1222)

Previous Vaccine:
AstraZeneca
(AZ = 615)

Previous Vaccine:
Pfizer
(Pf = 607)

PIL: Same as Previous Vaccine
(AZ = 205 / Pf = 205)

PIL: Different / Familiar Vaccine
(AZ = 204 / Pf = 200)

PIL: Different / Unfamiliar Vaccine
(AZ = 206 / Pf = 202)

Positive
(AZ = 103 / Pf = 104)

Negative
(AZ = 102 / Pf = 101)

Positive
(AZ = 101 / Pf = 100)

Negative
(AZ = 103 / Pf = 100)

Positive
(AZ = 103 / Pf = 100)

Negative
(AZ = 103 / Pf = 102)

Baseline Primary Outcome:

Baseline Booster Intention

'If you were offered [framed vaccine type] as a booster vaccine to maintain protection against COVID-19 viruses, how likely would you be to accept?' (100-point VAS)

Baseline Secondary Outcomes:

Baseline Perceived Booster Side effect Severity

'Overall, how severe do you think the [framed vaccine type] side effects are?' (100-point VAS)

Baseline Perceived Booster Risk

'What do you think the risk to your health would be if you received [framed vaccine type] as a booster vaccine, bearing in mind its side effects?' (100-point VAS)

Baseline Booster Acceptance

'Imagine that switching to the [framed vaccine type] vaccine was your only option for a booster. Please rate how satisfied, happy, and anxious, you would be with this outcome' (100-point VAS)

Manipulation: Timed presentation of framed PIL information

Post-Manipulation Primary Outcome:

Booster Intention

Post-Manipulation Secondary Outcomes:

Perceived Booster Side effect Severity

Perceived Booster Risk

Booster Acceptance

Post-Manipulation Judgement of Side Effect Prevalence

Assignment of PIL side effects to verbal risk brackets

Forced choice assignment to very common, common, uncommon, rare and very rare categories

Estimation of prevalence (X in every 100,000 individuals)

Estimation of how many people in every 100,000 affected

Negative Attribute Frame (Standard EU Wording)	Positive Attribute Frame	Positive Attribute Frame (Accompanying Infographic)
Common (may affect up to 1 in 10 people)	**Common** (90 in 100 or more people may **_not be affected_**)	**Common:** 90 in 100 (blue circles) or more **not affected**
Uncommon (may affect up to 1 in 100 people)	**Uncommon** (990 in 1,000 or more people may **_not be affected_**)	**Uncommon:** 990 in 1,000 (blue circles) or more **not affected**

3a. Frequency of Participants by Location

Scotland

1st dose 79.1%
2nd dose 71.6%
3rd dose 15.7%

Northern Ireland

1st dose 70.3%
2nd dose 65.8%
3rd dose 6.2%

England

1st dose 74.3%
2nd dose 67.8%
3rd dose 13.3%

Wales

1st dose 77.2%
2nd dose 70.9%
3rd dose 15.8%

Participant Frequency

10   20   30

3b. Demographic Information by Condition

Education by Condition

Other
Post–Graduate
Undergraduate
A–Level
NVQ1/NVQ2
GCSE
Primary/Secondary

Employment by Condition

Unemployed (looking)
Unemployed (not looking)
Student
Self–employed
Retired
Other
Parenting/caring
Part-time
Full-time

Positive Same
Positive Familiar
Positive Unfamiliar
Negative Same
Negative Familiar
Negative Unfamiliar

Age by Condition

Negative Unfamiliar
Negative Familiar
Negative Same
Positive Unfamiliar
Positive Familiar
Positive Same

0   25   50   75   100

Participant Age

25   50   75   100

4a. Booster Intention (Framing*Familiarity)

4b. Booster Intention (Framing*Familiarity*Baseline Intention)

4c. AstraZeneca Vaccine Switches

4d. Pfizer Vaccine Switch

4e. Side Effect Familiarity Ratings

Key: Framing — Negative Frame — Positive Frame